<DOC>
	<DOC>NCT02147197</DOC>
	<brief_summary>This study will evaluate the superiority of ulipristal acetate vs. placebo for the treatment of bleeding associated with uterine fibroids</brief_summary>
	<brief_title>A Study of the Efficacy and Safety of a Single Ulipristal Treatment Course for the Treatment of Abnormal Uterine Bleeding Associated With Leiomyomas</brief_title>
	<detailed_description />
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Leiomyoma</mesh_term>
	<mesh_term>Myofibroma</mesh_term>
	<mesh_term>Uterine Hemorrhage</mesh_term>
	<criteria>Premenopausal women, 1850 years, inclusive. Has experienced cyclic abnormal uterine bleeding (heavy or prolonged). Has a menstrual blood loss (MBL) of â‰¥ 80 mL as measured once by the alkaline hematin method during screening over the first 8 days of menses. Has a minimum of one discrete leiomyoma observable by transvaginal ultrasound at the screening assessment Has a history of uterine surgery that would interfere with the study endpoints. Has a known coagulation disorder including bleeding disorder or clotting disorder (e.g., von Willebrand disease or platelet disorder, factor V Leiden, prothrombin gene mutation, antiphospholipid syndrome). Has a history of, or current uterine, cervix, ovarian, or breast cancer.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>